This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring

Early Bird pricing expires in:

  • 00
  • 00
  • 00
  • 00
Delivered In-Person & Digitally
March 28–30, 2022, Basel, SwitzerlandApril 4–6, 2022, Digital Partnering

Stephanie Léouzon
Partner and Head at Torreya Europe


Stephanie Léouzon is Partner and Head of Torreya Europe. She has worked on over 100 strategic and financing transactions in the biopharmaceutical industry, with an aggregate value of over $75 billion.

Stephanie joined Torreya in 2011. Previously, she was a Managing Director and Senior Advisor at Credit Suisse in London. She has also worked at Salomon Brothers, as a Director of Healthcare Investment Banking, and as a Vice President in the Investment Banking divisions of JP Morgan, and Lehman Brothers in New York.

Highlights of Stephanie’s strategic advisory experience include the $34.6 billion Astra and Zeneca merger, the $6.8 billion Pharmacia & Upjohn merger, Hoechst’s $7 billion acquisition of Marion Merrell Dow; the creation of Syngenta through the merger of the agricultural businesses of AstraZeneca and Novartis; and the $3.1 billion Warner Chilcott LBO.

She has also led financings across several life sciences sectors, focusing on biotechnology and specialty pharma. She has worked on more than 15 Initial Public Offerings (IPOs) including Movetis, Warner Chilcott, Syngenta, GPC Biotech, Ark Therapeutics, Walsh International, IDEXX Labs, Viropharma, Pharmaceutical Marketing Services Inc., and Geron Corp. She has led Secondaries, Convertibles, Private Placements for, among many others, National Health Laboratories, Marion Merrell Dow, Oxford Glycosciences, BTG Therapeutics, Gilead Sciences, Skye Pharma, Centocor, Ark Therapeutics, American Medical Response, Pharmaceutical Marketing Services, Virco Holdings, and NaPro Biotherapeutics. A notable debt financing was the $2.4 billion bank and high yield financings for the LBO of Warner Chilcott.

Stephanie earned a B.A. cum laude from Mount Holyoke College and an M.A. and an M.B.A. from the Darden School at the University of Virginia.

She currently serves as a Non-Executive Director on the Board of BioPharma Credit PLC and also as a member of the Advisory Board for Great Ormond Street Hospital's Digital Research, Informatics and Virtual Environments (DRIVE) unit.

Agenda Sessions

  • In conversation with Philippe Lopes-Fernandes: partnering strategy at Ipsen


Speakers at this event